Promising results from a clinical trial of LP-10 suggest the drug could become the first FDA-approved therapy for symptomatic oral lichen planus (OLP).

LP-10, a proprietary liposomal tacrolimus oral rinse, was evaluated in a Phase IIa multicentre, dose-ranging clinical trial. Twenty-seven patients completed a four-week treatment course with no serious adverse events reported, with the trial achieving statistically significant improvements across all efficacy measures.  

The results offer hope that LP-10 could become the first FDA-approved therapy for OLP, a chronic inflammatory condition that affects an estimated six million people in the US which has no approved treatment options. 

“We believe these compelling results validate LP-10’s potential to address a large, underserved patient population,” said Jonathan Kaufman, CEO and Co-founder of Lipella. “The combination of excellent safety, minimal systemic absorption, and robust efficacy across multiple validated endpoints positions LP-10 as a first-in-class therapy. Based on these data, we are preparing to advance LP-10 into a pivotal Phase IIb study.” 

Oral lichen planus is a chronic inflammatory condition affecting the oral mucosa, characterised by white reticular lesions, erosions, and ulcerations that cause significant pain and functional impairment. Classified by the World Health Organization as an oral potentially malignant disorder, OLP carries a malignant transformation risk of approximately 1.4%.  

Despite affecting an estimated six million people in the US, there are currently no FDA-approved therapies, leaving patients to rely on off-label treatments with limited efficacy and concerning side effect profiles. 

“We believe LP-10 represents a paradigm shift in OLP treatment, if approved,” added Kaufman. “By delivering tacrolimus through our proprietary liposomal formulation as an oral rinse, we’ve overcome the delivery challenges that have limited topical treatments while maintaining an exceptional safety profile. These results strengthen our conviction that LP-10 has the potential to transform the treatment landscape for millions of patients living with this chronic condition.” 

Lipella Pharmaceuticals is planning on advancing LP-10 into late-stage development, including a Phase IIb clinical trial incorporating FDA feedback. 

 

Bruno Quinney, Content Team, DDW